Evaluate Data

Big pharma once again fails to dominate the top 20 expected best sellers from products due for launch this year. Small-to-medium pharma account for nearly half the list, while Vertex has two products in the top five.

Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.

Summit Therapeutics hit the stock market heights in 2024, along with a handful of biotech with novel therapies and platforms, while Moderna was dragged down by shrinking COVID-19 vaccine sales.

Evaluate data from the fourth quarter of 2024 show another period of venture capital fundraising that beat each quarter of 2023, as $100m-plus mega-rounds surged.

Evaluate data show that the biopharma industry made $9.5bn of acquisitions during the fourth quarter, a third consecutive quarter of decline, although deal volume rose to 33 from Q3’s 29.

Septerna is the best performer of newly launched firms from Q4, with more initial public offerings fuelled by potential interest rate cuts hoped for in 2025.

Just a handful of big pharma approvals of 2024 are tipped to be multi-billion dollar blockbusters. Even though it is still early days for these drugs, the pull of M&A is looking increasingly strong for big pharma as more smaller firms go it alone.

Just a handful of big pharma approvals of 2024 are tipped to be multi-billion dollar blockbusters. Even though it is still early days for these drugs, the pull of M&A is looking increasingly strong for big pharma as more smaller firms go it alone.

As the pharmaceutical sector evolves, the landscape of sales-driving indications is set for transformation by 2030. This article explores the therapeutic areas poised for substantial growth and examines how leading companies are strategically positioning themselves to capitalize on these emerging opportunities.

A flurry of big readouts are expected in the supercharged obesity/diabetes space, with Novo Nordisk looking to make up ground against its rival Eli Lilly.